Profile data is unavailable for this security.
About the company
Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company. The Company's technology, namely Fully Human Albumin Binding (FHAB), utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. The Company designed the FHAB construct to improve drug accumulation in cancer tumors, as well as to extend the duration of activity in the body. Its lead asset, SON-1010, is a fully human single-chain version of Interleukin 12 (IL-12), covalently linked to the FHAB construct, for which it is pursuing clinical development in solid tumors. Its lead clinical-stage asset, SON-080, is a fully human version of IL-6 manufactured in Chinese Hamster Ovary (CHO) cells. SON-080, for its target indications of Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN). Its pipeline also includes SON-1210, SON-1410 and SON-3015.
- Revenue in USD (TTM)92.74k
- Net income in USD-8.43m
- Incorporated1999
- Employees12.00
- LocationSonnet Biotherapeutics Holdings Inc100 Overlook Center, Suite 102PRINCETON 08540United StatesUSA
- Phone+1 (609) 375-2227
- Fax+1 (302) 636-5454
- Websitehttps://www.sonnetbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Geovax Labs Inc | 0.00 | -27.78m | 4.60m | 17.00 | -- | 77.40 | -- | -- | -14.42 | -14.42 | 0.00 | 0.0235 | 0.00 | -- | -- | 0.00 | -180.60 | -108.34 | -242.41 | -147.24 | -- | -- | -- | -1,842.93 | -- | -- | 0.00 | -- | -100.00 | -- | -85.20 | -- | -- | -- |
| Onconetix Inc | 758.90k | -45.68m | 4.61m | 12.00 | -- | -- | -- | 6.07 | -2.41 | -2.41 | 0.0407 | 1.91 | 0.0156 | -- | 4.70 | 63,241.67 | -93.67 | -- | -137.89 | -- | -123.62 | -- | -6,019.45 | -- | 0.2752 | -17.12 | 0.2352 | -- | -- | -- | -176.78 | -- | -- | -- |
| China Pharma Holdings Inc | 6.42m | -3.56m | 4.70m | 231.00 | -- | 0.5287 | -- | 0.7314 | -0.8352 | -0.8352 | 1.03 | 0.5596 | 0.3828 | 1.93 | 14.14 | 27,795.89 | -21.22 | -29.66 | -44.77 | -55.25 | -11.67 | 6.47 | -55.42 | -73.09 | 0.2523 | -11.34 | 0.261 | -- | -13.48 | -10.68 | 22.50 | -- | -25.78 | -- |
| Pineapple Inc | 157.59k | 376.69k | 4.75m | -- | 0.5834 | -- | 12.47 | 30.15 | 0.1114 | 0.1114 | 0.0028 | -0.0318 | 0.0388 | -- | -- | -- | 9.28 | -- | 53.43 | -- | -412.55 | -- | 239.03 | -- | 0.00 | -- | -- | -- | -- | -- | -611.10 | -- | -- | -- |
| NS Wind Down Co Inc | 162.47m | -166.43m | 4.81m | 703.00 | -- | -- | -- | 0.0296 | -3.53 | -3.53 | 3.44 | -1.05 | 0.4936 | 2.07 | 4.30 | 231,113.80 | -50.56 | -30.01 | -62.82 | -34.66 | 35.72 | 57.14 | -102.44 | -80.87 | 2.02 | -70.17 | 1.29 | -- | -12.28 | 2.06 | -38.43 | -- | 40.03 | -- |
| Lipella Pharmaceuticals Inc | 477.45k | -4.74m | 4.88m | 5.00 | -- | 1.76 | -- | 10.23 | -0.7633 | -0.7633 | 0.0747 | 0.3638 | 0.1232 | -- | 6.25 | 95,490.00 | -122.37 | -- | -146.33 | -- | -- | -- | -993.39 | -- | -- | -- | 0.00 | -- | 144.15 | -- | -77.81 | -- | -- | -- |
| Sonnet Biotherapeutics Holdings Inc | 92.74k | -8.43m | 4.89m | 12.00 | -- | 1.60 | -- | 52.69 | -5.28 | -5.28 | 0.0315 | 0.9813 | 0.0097 | -- | 0.2248 | 7,728.33 | -87.68 | -- | -194.11 | -- | -- | -- | -9,086.22 | -- | -- | -138.21 | 0.00 | -- | -57.76 | -- | 36.64 | -- | -- | -- |
| Emmaus Life Sciences Inc | 28.46m | -4.74m | 4.94m | 55.00 | -- | -- | -- | 0.1735 | -0.0931 | -0.0931 | 0.3905 | -0.6773 | 0.6349 | 0.8184 | 9.36 | 517,454.50 | -10.58 | -- | -- | -- | 93.69 | -- | -16.66 | -- | 0.1249 | 0.1426 | -- | -- | -10.77 | -- | 33.37 | -- | -- | -- |
| Soligenix Inc | 699.21k | -7.01m | 4.98m | 13.00 | -- | 4.31 | -- | 7.12 | -0.7395 | -0.7395 | 0.0725 | 0.073 | 0.073 | -- | 4.17 | 53,785.38 | -73.17 | -75.40 | -2,448.34 | -154.32 | 9.46 | 22.83 | -1,002.55 | -620.02 | -- | -- | 0.7959 | -- | -11.54 | -30.67 | 55.50 | -- | -- | -- |
| ProtoKinetix, Inc. | 0.00 | -400.47k | 5.01m | 0.00 | -- | 12.63 | -- | -- | -0.0012 | -0.0012 | 0.00 | 0.0011 | 0.00 | -- | -- | -- | -88.14 | -696.88 | -101.62 | -785.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 78.22 | -- | 10.78 | -- |
| GB Sciences Inc | 0.00 | -4.03m | 5.08m | 3.00 | -- | -- | -- | -- | -0.0105 | -0.0105 | 0.00 | -0.0119 | 0.00 | -- | -- | 0.00 | -255.86 | -49.16 | -- | -131.40 | -- | 6.03 | -- | -995.19 | -- | -8.63 | -- | -- | -- | -- | -2,715.25 | -- | -60.82 | -- |
| Stemtech Corp | 4.64m | -4.08m | 5.09m | 45.00 | -- | -- | -- | 1.10 | -0.0624 | -0.0624 | 0.0619 | -0.0092 | 1.09 | 8.35 | 65.16 | 103,098.40 | -96.70 | -- | -- | -- | 76.09 | -- | -88.58 | -- | 0.1045 | -1.81 | 2.27 | -- | -- | -- | -- | -- | -- | -- |
| Mystic Holdings Inc | -100.00bn | -100.00bn | 5.10m | 79.00 | -- | 0.2093 | -- | -- | -- | -- | -- | 0.2155 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.2228 | -- | 0.1849 | -- | 199.82 | -- | 34.32 | -- | -- | -- |
| CeCors Inc | -100.00bn | -100.00bn | 5.11m | 6.00 | -- | -- | -- | -- | -- | -- | -- | -0.0163 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 22.70 | -- | -- | -- |
Data as of May 30 2024. Currency figures normalised to Sonnet Biotherapeutics Holdings Inc's reporting currency: US Dollar USD
2.06%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| G1 Execution Services LLCas of 31 Mar 2024 | 34.45k | 1.12% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 14.73k | 0.48% |
| Virtu Americas LLCas of 31 Mar 2024 | 10.84k | 0.35% |
| Tower Research Capital LLCas of 31 Mar 2024 | 2.72k | 0.09% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 520.00 | 0.02% |
| Citigroup Global Markets, Inc. (Investment Management)as of 31 Mar 2024 | 38.00 | 0.00% |
| Wells Fargo Bank, NA (Private Banking)as of 31 Mar 2024 | 22.00 | 0.00% |
| Merrill Lynch, Pierce, Fenner & Smith, Inc. (Invt Mgmt)as of 31 Mar 2024 | 6.00 | 0.00% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024 | 6.00 | 0.00% |
| Private Wealth Management Group LLC (New Jersey)as of 31 Mar 2024 | 3.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
